复方阿利克仑/氢氯噻嗪片是诺华公司的产品（商品名：Tekturna HCT，在海外为Rasilez），用于降血压。本品是将直接抑制引起血压升高肾脏酶肾素的高血压治疗药阿利克仑与利尿药氢氯噻嗪相结合的降压药品。

阿利克仑的疗效可持续24小时及其以上这一点非常重要，因为许多抗高血压药都不能24小时奏效，尤其是在血压升高时的清晨。阿利克仑还显示最后一次给药后长达4日可维持降压作用。氢氯噻嗪通常被称为“排水药”，是使用最广泛的降压药。

研究数据显示，阿利克仑与氢氯噻嗪联合用药较单独使用其中任一种药物降压具有显著的相加作用。许多高血压患者常需两种或更多的药物来控制血压，新复方片减少了服用制剂的数量，简化了治疗方案。美国批准Tekturna HCT上市是基于对2700例患者采用阿利克仑加氢氯噻嗪的临床研究结果。

阿利克仑靶向作用于肾素和降低肾素系统的活性，可通过测定血浆肾素活性（PRA）获得数据。藉降低肾素活性，阿利克仑扩张血管使血压下降。利尿药氢氯噻嗪通过排除人体多余的水和盐，但增加PRA。

Tekturna HCT (Hydrochlorothiazide and Aliskiren)

Tekturna HCT is a combination of hydrochlorothiazide and aliskiren.

Hydrochlorothiazide is a thiazide diuretic (water pill) that helps prevent your body from absorbing too much salt, which can cause fluid retention.

Aliskiren (Tekturna) is an anti-hypertensive (blood pressure lowering) medication. It is a direct renin inhibitor and works by decreasing substances in the body that narrow blood vessels and raise blood pressure.

Tekturna HCT is used to treat high blood pressure (hypertension).

Tekturna HCT may also be used for other purposes not listed here.

TEKTURNA HCT 150/12.5

Indications for TEKTURNA HCT 150/12.5

Hypertension.

Adult dose for TEKTURNA HCT 150/12.5

Take consistently with regard to meals (absorption reduced by high-fat meals). ≥18yrs: 1 tablet once daily. Add-on or initial therapy and not volume-depleted: initially 150mg/12.5mg; may increase after 2–4 weeks up to max 300mg/25mg. Replacement therapy: may be substituted for the titrated components. Maximum effect usually seen at 4 weeks.

Children's dosing for TEKTURNA HCT 150/12.5

<18yrs: not recommended.

Also:

Contraindications for TEKTURNA HCT 150/12.5

Anuria. Sulfonamide allergy.

Warnings/Precautions for TEKTURNA HCT 150/12.5

Severe renal impairment (CrCl<30mL/min): not recommended. Severe renal disease. Correct salt/volume depletion before starting, or monitor closely. Hepatic dysfunction. Asthma. SLE. Monitor electrolytes. Pregnancy (Cat.D). Nursing mothers: not recommended.

Interactions for TEKTURNA HCT 150/12.5

Concomitant cyclosporine, lithium (risk of toxicity): not recommended. Potentiates antihypertensives, possibly non-depolarizing muscle relaxants. Potentiated by ketoconazole, atorvastatin. Antagonized by irbesartan, NSAIDs, cholestyramine, colestipol resins. May antagonize furosemide. ACTH, corticosteroids increase hypokalemia risk. Adjust antidiabetic drugs. Orthostatic hypotension potentiated by alcohol, CNS depressants.

Adverse Reactions for TEKTURNA HCT 150/12.5

Dizziness, diarrhea, cough, asthenia, arthralgia, elevated BUN/creatinine, ALT, uric acid; rare: angioedema (discontinue if occurs).

How is TEKTURNA HCT 150/12.5 supplied?

Tabs—30, 90

Generic Name for TEKTURNA HCT 150/12.5

Aliskiren 150mg, hydrochlorothiazide 12.5mg; tabs.

Legal Classification:

Rx

Pharmacological Class for TEKTURNA HCT 150/12.5

Direct renin inhibitor + thiazide.

Manufacturer of TEKTURNA HCT 150/12.5

Novartis Pharmaceuticals Corp

复方降压药Tekturna HCT获准作为一线降压药

Tekturna HCT是由直接肾素抑制剂Tekturna(阿利吉仑)与利尿剂氢氯噻嗪(HCTZ)配伍制成的复方片剂，最初于2008年1月在美国获准作为高血压的二线治疗药。该药由诺华公司生产